

Index

Note: Page numbers in italics refer to Figures; those in bold to Tables

- action myoclonus renal failure syndrome, **31**, **44**, 134
- adult onset, 18
- α -Mannosidosis, **42**, **110** *see also* glycoproteinoses
- case history, 111
 - clinical presentation, 112
 - enzyme defect, 108
 - epidemiology and prevalence, **32**, 107
 - gene (MAN2B1) mutations, 111–12
 - pathophysiology, 112
 - prognosis, 113
 - treatment, 113, 159
- angiokeratoma, **24**
- angiotensin converting enzyme (ACE), 61
- aspartylglucosaminuria, **42**, **110** *see also* glycoproteinoses
- epidemiology and prevalence, **31**, 107
 - mutations, 109
- Batten disease *see* neuronal ceroid lipofuscinoses (NCLs)
- β -Mannosidosis, **42**, **110** *see also* glycoproteinoses
- epidemiology and prevalence, **32**, 107
 - enzyme defect, 108
- blood brain barrier (BBB), 166
- brain ECF and CSF, 169
 - CNS storage and neuropathology, 166–7
 - damage in LSDs, 173
 - delivery of therapeutics across BBB, 171
 - mannose-6-phosphate and mannose receptors, 171
 - mouse BBB, 167, 168
 - neuronal death apoptosis, 166
 - neuronopathic LSDs, 166
 - plasma membrane and glycocalyx, 169
 - receptor-mediated transcytosis (RMT), 171, 172
 - substrate reduction therapeutics and chaperones, 171
 - substrate-specific solute carriers (SLCs), 169–70, **170**
 - transport routes across BBB, 172
- bone marrow transplantation (BMT), 99
- see also* haematopoietic stem cell transplantation
 - pre-symptomatic, 184
- burden of illness, 34, 153
- cardiac disease, 16
- cardiomyopathy, **23**
- carrier detection, 26
- cathepsins, **43**, 144–5
- cathepsin A deficiency (*see* galactosialidosis)
 - cathepsin C deficiency (*see* Papillon-Lefèvre)
 - cathepsin E, 145
 - cathepsin K deficiency (*see* pycnodystosis)
- cell complementation, 155
- chaperone therapy *see* pharmacological chaperone therapy
- Chédiak-Higashi syndrome, 30, **46**, 145–8, 146, 154–6
- cherry red spot, 17, 18, **25**, 65
- cholesteryl ester storage disease (CESD)/ Wolman disease, **43**, 143
- clinical diagnosis, 144
 - genetics and epidemiology, 144
 - hepatic fibrosis, 143
 - lysosomal acid lipase (LAL) deficiency, 143
 - pathophysiology, 143–4
 - prevalence, **31**
 - treatment, 144
- classification, 37, **39–46**
- clathrin-mediated endocytosis (CME), 4
- cobalmin-F transporter disease, 5, 25, **44**, 134–5
- coordinated lysosomal expression and regulation (CLEAR), 3
- cyclodextrin, 163
- cystinosis, **44**, 131
- clinical and biochemical study, 163
 - clinical forms, 131
 - cysteamine treatment, 163
 - Fanconi syndrome, 162
 - genetics, 131
 - laboratory diagnosis, 25, 133
 - management, 162
 - pathophysiology, 131
 - prevalence, **31**
 - systemic therapy, 163
 - thiol-disulphide interchange reaction, 162
 - topical therapy, 162
- Danon disease, 10, 26, 30, **31**, **44**, 133–4, 155

- deafness 16, 112
- diagnosis *see also* individual diseases
 chorionic villus sampling, 27
 clinical algorithm, 13, 14
 digital microfluidics, 27
 dried blood spots, 22, 27
 enzyme defects, panels, 22, 23–5
 enzyme deficiencies in plasma, 22, 22
 genome sequencing, 27, 183
 laboratory algorithm, 20, 21
 molecular genetic tests, 26, 29
 non-enzymatic defects, 25
 preliminary screening tests, 20, 21
 prenatal, 27
 protein profiling, 27
- dysmorphism, 13, 16, 23
- dysostosis multiplex, 17, 17, 23
- enzyme enhancement therapy (EET),
 156–9, 178, 179
- enzyme replacement therapy (ERT)
 alpha-mannosidosis, 159
 enzymatic augmentation, 157
 Fabry disease, 158
 Gaucher disease, 54, 157
 Hunter disease, 158
 Hurler–Scheie disease, 158
 intrathecal, 176
 licensed preparations, 157
 Maroteaux–Lamy disease, 158
 Morquio disease, 158
 Niemann–Pick disease type B, 159
 Pompe disease, 159
 targeting CNS, 176–7
- European Gaucher Alliance (EGA), 191
- European Study Group on Lysosomal
 Diseases (ESGLD), 37
- Fabry disease, 39, 58
 adjuvant therapy, 61
 α -galactosidase A deficiency, 58
 angiokeratomas, 59, 59
 diagnostic pathway, 60–61, 60
 enzyme replacement treatment, 61
 epidemiology, 58
 facial dysmorphism, 59–60, 60
GLA A gene, 58
 kidney biopsy, 61, 61
 life expectancy, 60
 pathophysiology, 59
 patient history, 58
 prevalence, 31
 symptoms, 59
 treatment guidelines, 61
- Farber disease, 40, 142
 acid ceramidase deficiency, 142
ASAH1 gene, 143
- clinical diagnosis, 143
 pathophysiology, 142–3
 prevalence, 31
 psychomotor development, 142
 treatment, 143
- fucosidosis, 42, 110 *see also*
 glycoproteinoses
 epidemiology and prevalence, 31, 107
 mutations, 109
- galactosialidosis, 42, 115
 cathepsin A and *CTSA* correlation,
 116–17
 clinical diagnosis, 117–18
CTSA genomic organization, 116, 116
 epidemiology, 115–16
 H&E staining, 118, 118
 nephropathy, 118–19
 NEU1 and PPCA, 117
 neurodegenerative lysosomal storage
 disorder, 115
 pathophysiology, 117
 patient history, 115
 PPCA antibody, immunohistochemistry,
 119, 119
 prevalence, 31
 recombinant AAV, 119
- gangliosidoses, 39, 63
 bone marrow, histiocytes storage,
 63, 64
 genetics, 63, 66, 66, 67
 GM1-gangliosidosis, 39
 classification, types I, II & III, 63–4
 epidemiology, 64
 patient history, 63
- GM2-gangliosidosis, 39
 classification, 64–5
 epidemiology, 65–6
 GM2-activator protein defect
 (AB variant), 65, 66
 patient history, 65
 Sandhoff disease, 5, 7, 22, 24, 25, 32,
 65, 66, 142, 173
 Tay–Sach disease, 17, 18, 22, 24, 25, 32,
 34, 39, 63–5, 66, 68, 81, 154, 173
- laboratory diagnosis, 67–8
 macular cherry red spot, 64–5, 65
 pathophysiology, 66–7
 treatment, 68
 urinary oligosaccharides, 63, 64
- Gaucher disease, 39, 49
 β -glucocerebrosidase deficiency, 55
 β -glucocerebrosidase gene mutation,
 49, 50
 biomarkers, 52
 bone disease, 54, 55
 chaperone therapy, 55
- diagnosis, 52
 Ehrlenmayer flask deformity, 50, 51
 epidemiology and prevalence, 31, 49
 enzyme replacement therapy (ERT), 49,
 54, 55, 156–7
 etiology and pathogenesis, 50
 hepatosplenomegaly, 50, 51
 malignancy, 55
 neurological signs and symptoms, 54
 osteopenia, 50, 51
 Parkinsonism, 51
 parotid gland biopsy, 51–2, 52
 pathological fracture, 50, 51
 patient history, 49
 QCSI, 52, 54
 SRT, 56
 subtypes and characteristics, 51–2, 53
 vertebral fracture, 50–51, 52
- genetic counselling, 35, 154
- genetics, 29–36
 carrier testing, 26, 181
 clinical heterogeneity, 29
 clinical progression rate, 30
 counselling, 35, 154
 gene location, mode of inheritance and
 symbol, 39–46
 genetic diagnosis, 26
- genomic imprinting in Niemann–Pick
 A/B, 30
 genotype-phenotype correlation,
 29, 182–4
- Guthrie screening card, 34–5
 incidence and prevalence of LSDs, 30,
 31–3
 late-onset patients, 29–30, 33–4, 183, 184
 newborn screening, 34, 182
 population screening program, 29
 populations at high risk, 34, 181
 pseudodeficiencies, 22
 sequencing, 27, 183
 X-linked LSDs, 30
- globoid cell leukodystrophy (GLD)/Krabbe
 disease, 40, 70
 clinical phenotype, 75
 enzymes and activator protein, 70, 71
 epidemiology and prevalence, 32, 72
 GALC activity, 74
 genotype/phenotype correlation, 72–3
 HSCT, 77–8
 laboratory diagnosis, 76–7
 lethal neurological symptoms, 70
 MRI, diagnosis, 76–7, 78
 mutations and polymorphisms, 72, 73
 natural disease course, 78
 pathophysiology, 74–5
 patient history, 70–71
 pseudodeficiency, 73–4

- glycoproteinoses, **42**, 107 *see also*
 individual diseases
 Asn-linked oligosaccharide degradation,
 107–8, 108
 BMT, 111, 113
 clinical presentation, 109
 enzymatic diagnosis, 112–13
 enzyme replacement therapy, 113
 epidemiology, 107
 genetics, 109, **110**
 genotype–phenotype relationship, 109
 laboratory diagnosis, 109
 pathophysiology, 111, 112
 prevalence, **31–2**
 glycosphingolipids
 lysosomal catabolism, 37, 38
 secondary storage, 7, 10
 GM1- and GM2-gangliosidosis *see*
 gangliosidoses
 GM2 activator defect, **39**
 Griscelli syndrome *see* lysosome biogenesis
 disorders
- haematopoietic stem cell transplantation
 (HSCT)
 globoid cell leukodystrophy, 77–8
 lysosomal biogenesis disorders, 156
 MPS I, 155
 MPS II, 155–6
 MPS VI, 156
 neurological disorders, 156
 haemophagocytic lymphohistiocytosis
 (HLH), 147, 148
 hepatosplenomegaly and liver disease,
 16–17, **24**
 Hermansky–Pudlak syndrome (HPS), **46**,
 145–6
 Hunter syndrome *see*
 Mucopolysaccharidosis II
 (MPS II)
 Hurler–Scheie disease *see*
 Mucopolysaccharidosis I
 Hurler syndrome *see*
 Mucopolysaccharidosis I
 hydrops foetalis (HF), 13, 15, **23**
- I-cell disease *see* mucopolipidosis II/III
 International Collaborative Gaucher
 Group (ICGG) registry, 55
- Kanzaki disease *see* Schindler disease
 Krabbe disease *see* Globoid Cell
 Leukodystrophy (GLD)
- late-onset patients, 29–30, 33–4, 183, **184**
 lysosomal membrane and transporter
 defects, **44**, 131, 132
- action myoclonus renal failure
 syndrome, 134
 cobalamin-F transporter (*see*
 cobalamin-F transporter disease)
 cystinosin (*see* cystinosis)
 diagnosis, 25–6
 equilibrative nucleoside transporter
 3, 144
 juvenile ceroid lipofuscinosis (*see*
 juvenile ceroid lipofuscinosis)
 LAMP-2 (*see* Danon disease)
 LIMP-2 (*see* action myoclonus renal
 failure syndrome)
 malignant infantile osteopetrosis, 132
 mucolipin (*see* mucopolipidosis IV)
 mutations, 131, 132
 Niemann–Pick C (NPC1), 135 (*see also*
 Chapter 11)
 physiological role, 131
 sialin (*see* sialic acid storage disease)
 sub-proteomic analysis, 135
- lysosomal system, 3, 4
 autophagy, 5
 axonal spheroids, 9, 9
 biogenesis, 156
 calcium signaling, 9–10
 canonical endocytic pathway, 4–5
 cellular mechanism, 3, 4
 clathrin-mediated endocytosis (CME), 4
 coordinated lysosomal expression and
 regulation (CLEAR), 3
 endocytosis, 3
 endolysosomal pathway, 3–4, 30
 greater lysosomal system, 3
 meganeurites and ectopic
 dendritogenesis, 10
 metabolic regulatory network, 3
 metabolic signatures, 8
 recycling molecular precursor, 3
 salvage, 5
 transcription factor EB (TFEB), 3
 ubiquitin-proteasome system (UPS), 5–6
- lysosome biogenesis disorders, **46**, 145,
 156
 Chédiak–Higashi syndrome, 30, **46**,
 145–8, 146, 154–6
 Griscelli syndrome, **46**, 147, 148, 155
 Hermansky–Pudlak syndrome (HPS),
46, 145
- malignant infantile osteopetrosis, **44**
 Maroteaux–Lamy disease *see*
 Mucopolysaccharidosis V
 metachromatic leukodystrophy (MLD),
39, 70
 clinical phenotype, 75
 arylsulphatase A and saposin B, 70, 71
- epidemiology and prevalence, **32**, 72
 genotype/phenotype correlation, 72, 74
 laboratory diagnosis, 76–7
 lethal neurological symptom, 70
 MRI, diagnosis, 75–6, 77
 mutations and polymorphism, 33, 72, **73**
 natural disease course, 70, 78
 pathophysiology, 74–5
 patient history, 70–71
 pseudodeficiency, 73–4
 treatment, 77
- Morquio disease *see*
 Mucopolysaccharidosis IV
 mucopolipidosis I *see* sialidosis
 mucopolipidosis II and III, **32**, **43**, 121
 biochemical missorting, 125–6
 birth and fatal outcome, 124–5
 chorionic villus sampling, 126
 classification and nomenclature, 121, **122**
 clinical diagnosis and symptoms, 16,
 123–4, **124**
 diagnostic pathway, 125, 126
 epidemiology, 122
 GNPTAB and GNPTG genes, 122, 124
 ML II alpha/beta (I-cell disease), 121–2,
 123
 ML III alpha/beta (pseudo-Hurler
 polydystrophy), 122
 ML III gamma (ML III variant), 122, 123
 pathophysiology, 123
 progressive disorder, 124
 transport defects, 121
 treatment, 126
- mucopolipidosis IV, **32**, 33, **44**, 132
 Mucopolysaccharidoses (MPS) *see also*
 Mucopolysaccharidosis I, II, III, IV,
 V, VI, VII & IX
 classification, **40–41**, 94, **95**
 clinical parameter correlation, 97, 99
 disease manifestation, 96–7
 dysostosis multiplex, 95–6, 96
 glycosaminoglycan analysis, 97, 98
 epidemiology and prevalence, **32**, 94
 GAG evaluation, 97
 GAG storage, 8–9
 gene therapy, 99–100
 genetics, 94–5
 intrathecal enzyme delivery, 176
 laboratory diagnosis flowchart, 97, 98
 neurodegenerative phenotype, 96, 97
 pathophysiology, 95
 patient history, 94
 phenotypic variability, 94
 skeletal phenotype, 96, 97
 therapy, **99**, 100, 158, 176–8
 treatment guidelines, 100
 visceral phenotype, 95–6, 96

- Mucopolysaccharidosis I, MPS I, Hurler, Hurler /Scheie and Scheie syndrome, 16, 17, 26, 30, **32**, **40**, 94, 100, 155, 158
- Mucopolysaccharidosis II, MPS II, Hunter disease, 26, 30, **32**, **41**, 94, 95, 155–6, 158
- Mucopolysaccharidosis III A, B, C & D, MPS III/Sanfilippo syndrome, 18, **32**, **41**, 94, 154, 157
- Mucopolysaccharidosis IV A & B, MPS IV/Morquio disease, **32**, **41**, 94, 158
- Mucopolysaccharidosis VI, MPS VI/ Maroteaux-Lamy disease, **32**, **41**, 94, 156, 158
- Mucopolysaccharidosis VII, MPS VII/Sly disease, **32**, **41**, 94
- Mucopolysaccharidosis IX, **32**, **41**, 94
- multiple sulfatase deficiency (mucosulfatidosis), **43**, 127
- biochemical basis, 127–9
 - clinical presentation, 127
 - diagnosis, 25, 129
 - genetic basis, 127
 - pathophysiology, 129
 - prevalence, **32**, 127
 - SUMF1, 127, 128
 - treatment, 129
- neurological aspects *see* blood brain barrier and Chapter 21
- clinical presentation, 17–18
 - CNS involvement, 6–7, 176
 - CNS storage and neuropathology, 166
 - neurodegeneration, 6, 7, 10, 166
- neuronal ceroid lipofuscinoses (NCLs), 26, **45**, 137
- AAVs, 140
 - characteristic pathology, 137
 - classification scheme, 137
 - case history, CLN2 disease, 137–8
 - case history, CLN3 disease, 138
 - clinical diagnosis, 18, 137
 - cysteamine and CLN1 disease, 163
 - epidemiology and prevalence, **31**, 138
 - ERT, 140
 - genetic basis, 138
 - genetic diagnosis, 138–9
 - laboratory diagnosis, 26, 139–40
 - pathophysiology, 139
 - symptom control and supportive approach, 140
 - treatment guidelines, 141
 - newborn screening, 182–3, **184**
- Niemann–Pick disease types A and B (NPD A and B), **40**, 80
- acid sphingomyelinase (ASM) deficiency, 82, 83
 - clinical and laboratory diagnosis, **84**
 - clinical presentation, types A & B, 80
 - disease pathogenesis, 82
 - EHS, 85
 - epidemiology and prevalence, **32**, 80–81
 - genetics, 81
 - genomic imprinting, 30, 81
 - hepatosplenomegaly, 82
 - IGF-1 signaling pathway, 82
 - life threatening complications, 83
 - pathophysiology, 81
 - pulmonary disease, 83
 - Purkinje cell death, 82
 - sphingomyelin, 81–2
 - treatment, 84–5, 159
- Niemann–Pick disease type C (NPC1 & 2), **44**, 87
- autosomal recessive metabolic disorder, 87
 - case histories, 87–8
 - cataplexy, 18
 - cholestatic jaundice, 87
 - clinical aspects, 89, 89, 91
 - cyclodextrin and Niemann–Pick C, 163
 - diagnostic and management guidelines, 92
 - dysarthria, 88
 - dystonia, 89, 91
 - epidemiology and prevalence, **32**, 88
 - filipin staining, 91, 92
 - foetal ascites, 91
 - genetics of NPC 1 and NPC 2, 88
 - hepatosplenomegaly, 87
 - laboratory diagnosis algorithm, 90, 91
 - LDL-induced cholesterol esterification, 91
 - pathophysiology, 88–9
 - progressive neurodegenerative disease, 89, 89
 - psychiatric symptom, 91
 - salvage process, 5
 - screening test, 91–2
 - sphingomyelinase deficiency, 91
 - treatment, 92
- oculo-cutaneous albinism, 147
- Papillon-Lefèvre, **43**, 144–5
- pathogenesis and pathophysiology
 - altered lipid trafficking, 166
 - autophagy dysfunction, 9–11, 9, *11*, 167
 - axon spheroids, 9, 9, 167
- calcium homeostasis and signaling, 9, 167
 - dysfunctional storage cell, 174, *175*
 - end-stage effects, 174
 - ectopic dendritogenesis, 10, 167
 - inflammation, 7, 176
 - intracellular storage, 7, 8
 - lysosomal system, *175*
 - meganeurites, 10, 167
 - oxidative stress, 166
- patient perspective on rare diseases 186
- definition of rare disease, 186
 - European perspective, 190–191
 - genetic origin, 187
 - health care, strategic decision, 186–7
 - LSD Patient Organisation Collaborative, 188
 - multidisciplinary care, LSD, 190
 - National (UK) perspective. 189–90
 - number of doctors seen before diagnosis, 188
 - political awareness, 190
 - prevalence, 186
 - prevention, 191
 - rationalisation and cost-effectiveness analysis, 190
 - risk sharing, 189
 - scale of problem, 186–7
 - screening technology advancement, 186
 - strategy for management of rare diseases, 191
 - time to diagnosis, *184*
 - treatment accessibility, 188–9
- pharmacological chaperone therapy, 160–161, 179
- β -Galactosidase deficiency, 161
 - Fabry disease, 161
 - Gaucher disease, 161
 - mode of action, 160
 - Pompe disease, 161
 - therapeutic principle, 160
- Pompe disease, **42**, 101
- cardio-respiratory insufficiency, 103–4
 - diagnosis, flow diagram, 104
 - enzymatic and molecular diagnosis, 104–5
 - epidemiology and prevalence, **32**, 103
 - ERT, 105, 159
 - facioscapulohumeral muscular dystrophy, 102
 - genetics, 103
 - glycogen storage disease type II, 102–3
 - hypertrophic cardiomyopathy, 103
 - life expectancy, 104
 - muscle biopsy, 101, *102*
 - pathophysiology, 103
 - prophylactic treatment, 105

- scapular winging, 101–2, 102
 symptoms, 104
 treatment guidelines, 105
 prenatal diagnosis, 27, 39–46
 prevalence of LSD, Table, 31–3
 prosaposin deficiency, 25, 33, 39
 protective protein *see* galactosialidosis
 pseudodeficiency of lysosomal enzyme
 activity, 22, 33, 39, 73
 pseudo-Hurler polydystrophy *see*
 mucopolipidosis II/III
 pulmonary fibrosis, 147–8
 pycnodysostosis, 33, 43, 144–5
- quantitative chemical shift imaging
 (QCSI), 52, 54
- Salla disease *see* sialic storage disease
 Sandhoff disease *see* gangliosidoses
 Sanfilippo syndrome *see*
 Mucopolysaccharidosis III
 saposin A defect, 32, 40 *see also* globoid
 cell leukodystrophy
 saposin B defect, 32, 39 *see also*
 metachromatic leukodystrophy
 saposin C defect, 31, 39 *see also* Gaucher
 disease
- Scheie disease *see* Mucopolysaccharidosis I
 Schindler/Kanzaki disease, 42, 110 *see also*
 glycoproteinoses
 epidemiology and prevalence, 31, 107
 screening, 181
 carrier detection, 26, 182
 criteria, 183, 183
- late-onset patients, 34, 183, 184
 newborn, 34, 78, 182–3, 183, 184
 high risk populations, 34, 182, 182
 methodology, 34, 183
- sialic acid storage disease, 33, 44, 132–3
 sialidosis (mucopolipidosis I), 42, 110 *see also*
 glycoproteinoses
 enzyme defect, 22, 108
 genotype/phenotype correlation 109
 mutations and prevalence, 32, 107
- Sly disease *see* Mucopolysaccharidosis VII
 sphingolipid activator proteins (saposins)
 defects, 22, 38, 39–40, 70
 stuttering, 43, 148
- substrate reduction/restriction therapy
 (SRT)
 Gaucher disease, 56, 160
 mode of action, 159
 Niemann-Pick disease type C, 160
 sphingolipidoses, 159–60
 sub-unit c of mitochondrial ATP
 synthase (SCMAS), accumulation,
 7–8, 8
- Tay–Sach disease *see* GM1-gangliosidosis
 transport defects *see* lysosomal membrane
 defects
- treatment *see* Chapters 20 and 22 and
 individual therapies
 anti-inflammatory drugs, 179
 antisense oligonucleotides, 178
 cell complementation (*see also*
 haematopoietic stem cell
 transplantation)
- combination therapies, 179
 comprehensive clinical care, 153
 enzyme replacement therapy (ERT),
 156, 178–9
 gene therapy, 156, 177–8
 induced pluripotent stem cells
 (iPSCs), 178
 lysosomal membrane stabilizers
 (HSP70), 179
 nanotechnology, 177
 neurological support, 154–5
 pharmacological chaperone therapy,
 160–161, 179
 pre-symptomatic bone marrow
 transplantation, 184
 read through of stop codons, 178
 RNA interference (iRNA), 178–9
 skeletal disease treatment, 176
 sleep disturbance, agitation, mood and
 seizure control, 154
 stage-specific therapy, 174, 179
 substrate removal/dispersal, 161–3
 substrate restriction/reduction therapy
 (SRT), 159–60
 supportive and palliative, 153
 surgical intervention, 154
 tonsillectomy and adenoidectomy, 154
- ubiquitin-proteasome system (UPS),
 5–6
 upper airway obstruction, 16
- Wolman disease *see* cholesteryl ester
 storage disease

